Results 11 to 20 of about 35,256 (161)

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach

International Journal of Infectious Diseases, 2021
Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response, causing severe manifestations during COronaVIrus Disease-2019 (COVID-19).
Alessandra D’Abramo, Serena Vita, Gaetano Maffongelli, Andrea Mariano, Chiara Agrati, Concetta Castilletti, Delia Goletti, Giuseppe Ippolito, Emanuele Nicastri   +8 more
doaj   +1 more source

Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases [PDF]

Archive of Oncology, 2009
Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all ...
Pejčić Ivica, Vrbić Svetislav
doaj   +1 more source

Monoclonal antibody-based therapies for Waldenström's macroglobulinemia

Leukemia Research Reports, 2022
Monoclonal antibodies have established an important role in the treatment armamentarium of hematological malignancies, including Waldenström's macroglobulinemia.
Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis   +2 more
doaj   +1 more source

Anti-CD20 monoclonal antibodies: reviewing a revolution [PDF]

Human Vaccines & Immunotherapeutics, 2018
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of ...
J. M. L. Casan, J. Wong, M. J. Northcott, S. Opat   +3 more
openaire   +3 more sources

The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies

Virulence, 2022
The optimal interval before receiving SARS-COV-2 vaccination for patients who have received anti-CD 20 monoclonal antibodies remains unclear. We considered original studies up to 29 October 2022 and conducted searches in Embase,Medrxiv, PubMed, and SSRN.
Kexin Liu, Jinyu Li, Gaosi Xu
doaj   +1 more source

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Haematologica, 2021
Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies, suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral ...
Ronit Gurion, Uri Rozovski, Gilad Itchaki, Anat Gafter-Gvili, Chiya Leibovitch, Pia Raanani, Haim Ben-Zvi, Moran Szwarcwort, Mor Taylor-Abigadol, Eldad J. Dann, Nurit Horesh, Tsofia Inbar, Inna Tzoran, Noa Lavi, Riva Fineman, Shimrit Ringelstein-Harlev, Netanel A. Horowitz   +16 more
doaj   +1 more source

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies [PDF]

Current Opinion in Immunology, 2008
The anti-CD20, B-cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis. Under conditions of high B cell burden, exhaustion of the body's effector mechanisms, for example, NK-cell-mediated killing, may lead to substantial decreases in the immunotherapeutic efficacy of this mAb ...
Ronald P, Taylor, Margaret A, Lindorfer
openaire   +2 more sources

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Haematologica, 2011
Background Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.
Mounia Sabrina Braza, Bernard Klein, Geneviève Fiol, Jean-François Rossi   +3 more
doaj   +1 more source

The Role of Monoclonal Antibodies in the Management of Leukemia

Pharmaceuticals, 2010
This article will review the monoclonal antibodies more commonly used in leukemias. In the last three decades, scientists have made considerable progress understanding the structure and the functions of various surface antigens, such as CD20, CD33.
Mohamad Cherry, Aref Al-Kali, Ali Al-Ameri, Alessandra Ferrajoli   +3 more
doaj   +1 more source

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies

Frontiers in Immunology, 2022
Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients.
Jennifer R. Blase, David Frame, Thomas F. Michniacki, Kelly Walkovich   +3 more
doaj   +1 more source